$CRH

A federal judge dismissed a proposed class action against CRH Healthcare, doing business as Peachtree Immediate Care, over claims that website tracking technologies (including Google Analytics) transmitted patients’ protected health information to third parties. The court said the plaintiff failed to show compensable damages and found an ECPA exemption for parties to the communication. The plaintiff has 14 days to amend.

Global Cement Newsletter reviews 1H 2026 results for major cement producers outside China. CRH sales rose on Eco Material Technologies and higher aggregates prices; Heidelberg Materials saw slight cement revenue declines except North America; Holcim reported 5% organic growth. Cemex’s Mexico strength lifted sales and volumes; UltraTech Cement sales rose 16% YoY to US$2.57bn in 1Q FY2027. Also covers Ararat Cement management change, IKN Czech appointment, and Mitsubishi UBE Cement IPO plans.

CRH said it acquired Pisgah Stone Products LLC to expand its Northern Utah aggregates network via CRH Americas Materials. The deal adds Pisgah quarry operations in Wellsville, Utah, supplying hard-rock limestone for asphalt and ready-mixed concrete. Financial terms were not disclosed. CRH cited strong regional population and infrastructure demand.

CRH’s Americas Materials unit said it acquired Pisgah Stone Products LLC, a Northern Utah aggregates producer. CRH expects the deal to add hard-rock limestone reserves to support its long-term regional strategy amid construction and infrastructure demand. Pisgah, based in Wellsville, supplies limestone for asphalt and concrete, serving business and government customers.

CRH reported 2Q26 revenues of US$10.8bn, up 6% year over year, and net income up 13% to US$1.5bn. Adjusted EBITDA rose 7% to US$2.6bn, with margins improving. CRH completed three non-core divestments and invested US$1.4bn in 17 acquisitions YTD, and agreed to buy Arcosa for US$8.5bn. It reaffirmed 2026 guidance: net income US$3.9-4.1bn, adjusted EBITDA US$8.1-8.5bn, EPS US$5.60-6.05.

CNBC’s Jim Cramer warned investors against buying AI or data-center stocks on margin as U.S. margin debt rose above $1.5 trillion. FINRA reported June debit balances at $1.502T, up 49% from a year earlier. Cramer said margin can trigger forced selling if prices fall. He cited CRH (CRH) as a more diversified data-center-linked option, noting Q1 revenue of $7.37B and guidance for 2025 net income $3.9B-$4.1B.

CRH shares fell about 1% after Q2 2026 earnings, following declines of roughly 10% over one month and 18% over three months. In Q2 2026, CRH reported US$10.8b revenue and adjusted EBITDA of over US$2.6b, with adjusted EPS of US$2.23. Management kept full-year guidance and emphasized margin expansion, while deal and integration risks were cited.

Citigroup lowered its price target on CRH public to $122 from $138 while keeping a Buy rating, according to the note cited in the article. The stock was shown around $95.64 at 11:18am EDT. Stephens also adjusted its target to $125 from $135, maintaining an Overweight rating.

CRH reported Q2 adjusted EBITDA of $2.63B, above analysts’ $2.59B estimate, with revenues up 6% to $10.88B. The company reiterated 2026 guidance: net income $3.9B to $4.1B and EBITDA $8.1B to $8.5B. CRH is working to close its $8.5B Arcosa acquisition within eight months.

CRH reported Q2 2026 revenues up 6% to $10.8 billion, net income up 13% to $1.5 billion, adjusted EBITDA up 7% to $2.6 billion, and diluted EPS up 14% to $2.21, citing pricing momentum, demand, and acquisitions. The company reaffirmed full-year guidance and completed $1.1 billion of acquisitions and $1.7 billion of net divestiture proceeds.